Company Overview of Iroko Pharmaceuticals Inc.
Iroko Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the development and commercialization of nonsteroidal anti-inflammatory drug therapeutics for patients to moderate acute and chronic pain. It provides Indocin for the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute painful shoulder, and acute gouty arthritis; and Aldomet to treat hypertension. The company’s products under development include Zorvolex, a formulation of diclofenac to treat acute pain in adult patients, as well as completed the Phase III clinical trials for the treatment of osteoarthritis pain; Tiforbex, a formulation of indomethacin that has completed the Phase III clini...
One Kew Place
150 Rouse Boulevard
Philadelphia, PA 19112
Founded in 2012
Key Executives for Iroko Pharmaceuticals Inc.
Chief Executive Officer and President
Executive Chairman of the Board
Chief Financial Officer and Principal Accounting Officer
Senior Vice President and Chief Medical Officer
Compensation as of Fiscal Year 2014.
Iroko Pharmaceuticals Inc. Key Developments
Iroko Pharmaceuticals Announces New Strategic Agreement to Commercialize ZORVOLEX(R) in Brazil
Jul 15 14
Iroko Pharmaceuticals, LLC announced that its affiliate, Iroko Pharmaceuticals Inc., has signed a licensing agreement with EMS around the exclusive rights to market and sell ZORVOLEX(R) (diclofenac) capsules in Brazil. EMS will be responsible for obtaining regulatory and pricing approval, as well as the marketing and supply of the medication, in that territory. ZORVOLEX was approved by the United States Food and Drug Administration (FDA) in October 2013 for the treatment of mild to moderate acute pain in adults and is now available by prescription. ZORVOLEX is not currently approved for marketing in any other country. Iroko will continue to retain all marketing rights to ZORVOLEX in the United States. In late 2013, Iroko entered into strategic agreements with Algorithm SAL and PT Pratapa Nirmala (Fahrenheit), under which the two companies obtained the exclusive rights to market and sell ZORVOLEX in countries in the Middle East, North Africa (MENA) and Indonesia, respectively.
Iroko Pharmaceuticals Reports 1st Regulatory Submission Outside U.S. for ZORVOLEX
Jul 11 14
Iroko Pharmaceuticals reported its affiliate's first regulatory submission outside of the United States for ZORVOLEX (diclofenac) capsules. The new drug application was filed for the nonsteroidal anti-inflammatory drug (NSAID) with the Republic of Lebanon Ministry of Public Health (MOPH). ZORVOLEX was approved by the U.S. Food and Drug Administration (FDA) in October 2013 for the treatment of mild to moderate acute pain in adults and is not currently approved for marketing in any other country. A supplemental New Drug Application seeking approval for osteoarthritis pain is currently being reviewed by FDA. This filing was the result of a licensing agreement signed late last year by the company's affiliate, Iroko Pharmaceuticals Inc., and Algorithm S.A.L. under which Algorithm obtained the exclusive rights to market and sell ZORVOLEX to countries in the Middle East and North Africa (MENA).
Algorithm SAL Signs a Licensing Agreement with Iroko Pharmaceuticals in South Philadelphia
Jul 8 14
Algorithm SAL signed a licensing agreement with Iroko Pharmaceuticals in South Philadelphia, filed a new drug application with the Republic of Lebanon Ministry of Public Health seeking approval for Zorvolex. Zorvolex is an Iroko product that was approved by the Food and Drug Administration in October 2013 as a treatment for mild-to-moderate acute pain in adults. Iroko has an application to also market the drug for osteoarthritis pain that is under review by the FDA. Algorithm's licensing deal gave it the right to sell Zorvolex in the Middle East and North Africa. Iroko will continue to retain all marketing rights to Zorvolex in the United States, where the drug became available at the start of this year, and is in discussions with additional companies to bring the drug to other international markets.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|